KRAS and cancer: Additionally, a recent breakthrough discovery on significant anticancer properties of recently approved FDA drugs, namely Sotorasib (AMG 510), in subjects with solid tumors (non-small cell lung carcinoma, colon, etc.)harboring the KRAS p.G12C mutation has shed light on cancer gene therapy.